Dr. Daniel Watkins is a Co-Founder & serves as Managing Director & Member of Investment Team at Mercury Fund. Dr. Daniel Watkins serves as Board Member at Vertos Medical. He serves as Board Member & Secretary at Resonant Therapeutics. He also serves as a Board Observer at Sinopsys Surgical. He focuses on startups utilizing software, cloud computing and/or machine learning to drive the next wave of scientific innovation in healthcare, agriculture and other industrial markets. Dan currently serves on the boards of Mercury portfolio companies Benson Hill, Clean Chemistry, Deep Imaging, DNAtrix, Resonant, Sinopsys and Swift Biosciences. Dan's previous investments at Mercury have included Cgate Health (acq. by SCI Solutions). Prior to co-founding Mercury, Dan served in a number of operational roles including CEO of DNAtrix and Nanospectra Biosciences, both startup oncology companies. Previously, Dan was Vice President at a boutique investment banking firm and Worldwide Manager of Operations and Control Systems for Scientific Software-Intercomp (Baker Hughes). Dan received his B.S. from Rice University and his M.S. and Ph.D. from Carnegie Mellon University, all in Materials Science. Dan is also a co-founder of the Rice Alliance for Technology and Entrepreneurship at Rice University. Outside of Mercury, Dan serves on the advisory boards of Northwestern University's Innovation and New Ventures Office (INVO), the Rice Alliance, the University of Michigan's Venture Center Council and the University of Illinois Proof of Concept Fund Committee.